Mary Ann Liebert Inc.: Lower Than Expected Risk of Bone Density Decline With Truvada PrEP
July 15, 2019
July 15, 2019
NEW ROCHELLE, New York, July 15 -- Mary Ann Liebert Inc. issued the following news release:
Researchers have shown that among users of pre-exposure prophylaxis (PrEP) to prevent against AIDS that includes tenofovir (Truvada), those with daily use - very high adherence - had only about a 1% average decrease in bone mineral density in the spine and a 0.5% decline in the hip. The study findings and the implications for the lower than expected results on the potential for broader use of . . .
Researchers have shown that among users of pre-exposure prophylaxis (PrEP) to prevent against AIDS that includes tenofovir (Truvada), those with daily use - very high adherence - had only about a 1% average decrease in bone mineral density in the spine and a 0.5% decline in the hip. The study findings and the implications for the lower than expected results on the potential for broader use of . . .